PATENT CLAIM ANALYSIS

Application Number: 15866544
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["514", "248000"]

Abstract:
A pharmaceutically acceptable composition and method for leukemia therapy in a patient in need of such therapy. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, (b) an inhibitor of Dusp-1, and (c) an inhibitor of BCR-ABL tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for leukemia.

Claim (Index 2):
The method of  claim 1  where (a) is an inhibitor of a c-Fos gene, (b) is an inhibitor of a Dusp-1 gene, and (c) is an inhibitor of a BCR-ABL tyrosine kinase gene.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 86.0
- Lexical Diversity: 1.79545
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14048806', '15579531', '14440001', '13265716', '14354822']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7417536771824177
- 35 USC 102 Novelty (BERT): 0.6997952971237175
- Combined Prediction Score: 0.7375578391765477
- Mean Citation Score: 405.07634999999993
- Max Citation Score: 710.12537
- Similarity Product: 703.561588403138

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test